Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 550.5 DKK 3.19% Market Closed
Market Cap: 39.1B DKK

EV/EBIT
Enterprise Value to EBIT

-24.5
Current
-17.5
Median
3.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-24.5
=
Enterprise Value
31B DKK
/
EBIT
-1.3B DKK
Market Cap EV/EBIT
DK
Zealand Pharma A/S
CSE:ZEAL
38.9B DKK -24.5
FR
Pharnext SCA
OTC:PNEXF
6T USD -209 659.2
US
Abbvie Inc
NYSE:ABBV
361.9B USD 25.3
US
Amgen Inc
NASDAQ:AMGN
165.1B USD 28.9
US
Gilead Sciences Inc
NASDAQ:GILD
139.4B USD 14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.7B USD 27.3
US
Epizyme Inc
F:EPE
94.1B EUR -518.5
AU
CSL Ltd
ASX:CSL
122.4B AUD 21.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
70.3B USD 11.5
US
Seagen Inc
F:SGT
39.3B EUR -55
NL
argenx SE
XBRU:ARGX
33B EUR -2 302.4
EBIT Growth EV/EBIT to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBIT: 21.5
Negative Multiple: -24.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 659.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.3
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
28.9
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.3
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -518.5 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.5
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 302.4 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-19.3
2-Years Forward
EV/EBIT
-39.8
3-Years Forward
EV/EBIT
-33.5